Windlas Biotech share price today

Windlas Biotech Ltd's share price was ₹873.45 at the close on 4 November 2026. It has been rising for 13 weeks. That is 3.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹723 and ₹1,129, and at that close it sat 37% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Windlas Biotech Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Over the last 5.2 years the share price moved +138% while the NIFTY 500 moved +55%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and foreign funds (FIIs) raised their stake for 3 quarters in a row.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹248 crore, +18.1% on a year earlier.

   Why: Revenue rose because the CDMO business brought in more work from existing customers and new product launches. That business led the quarter.

   From the earnings call on 11 Aug 2026.

2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 11.8% to 7.2% of the company by the September 2026 quarter.

3. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 0.6% to 2.1% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Windlas Biotech reported revenue of ₹248 crore, up 18.1% from ₹210 crore a year earlier, and a profit of ₹18.0 crore, up 0.0% from ₹18.0 crore.

Windlas Biotech results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Windlas Biotech's management discussed these results on a call held on 11 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Windlas Biotech closed at ₹873.45 on 4 November 2026, up 0.4% from ₹869.85 a year earlier (7 November 2025) and up 181.8% over five years. Its highest weekly close since August 2021 was ₹1,144.25 on 6 December 2024.

Windlas Biotech share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

277 weekly closes from 20 August 2021 to 4 November 2026.

4 Nov 2026: Windlas Biotech closed at ₹873.45, down 0.3% on the week and down 19.3% on the month. 11 Aug 2026: Windlas Biotech held its results call for April to June 2026. Management guided: Plant 6 commercialization planned by end-July to September 2026, with a roughly two-week variance.

Earlier

• 16 Jul 2026: ex-date for a dividend of ₹6.30 a share.
• Results for April to June 2026: Revenue up 18.1% and profit up 0.0% on a year earlier.

Windlas Biotech paid ₹6.30 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.72% at the ₹873.45 close on 4 November 2026. The last was a dividend of ₹6.30 a share, ex-date 16 July 2026.

Windlas Biotech dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Windlas Biotech Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 11 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 11 August 2026, Windlas Biotech's management guided: Plant 6 commercialization planned by end-July to September 2026, with a roughly two-week variance.

“The momentum has taken a hit, but I would say that this is a temporary hit for a few quarters rather than a long-term issue.”Komal Gupta, CEO & CFO, on the call for April to June 2026

What management guided

• Plant 6-supported total revenue ₹1,100 crore initially, with further ₹100-150 crore possible through efficiency and debottlenecking.
• Peak utilization of 60-65%, stretchable around 70% as operational capacity expands.
• Initial Plant 6 depreciation around ₹30 million per quarter, +/- 10-15%; partial impact starts at commissioning and full effect in the following quarter.
• Injectables capacity addition would take 6-8 months from decision through qualification and commissioning; no decision announced.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 11 August 2026.

When Windlas Biotech reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Plant 6 commissioning milestone - check validation completion, customer approvals and initial revenue and cash-flow conversion.

Windlas Biotech is on one of our India lists: Pharma stocks.

Windlas Biotech Ltd earned ₹18.0 Cr of net profit in the Jun 2026 quarter, +0.0% on the same quarter a year earlier. Full-year FY26 profit was ₹66.0 Cr. Over 10 years profit has grown 29.4% a year on average. That is 7.3% of the quarter's revenue. The same quarter a year earlier earned ₹18.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹66.0 Cr (+8.2% on the year before).

Why profit moved: revenue changed +18.1% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +3.1% and revenue +18.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

Windlas Biotech Ltd reported ₹248 Cr of revenue in the Jun 2026 quarter, +18.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 12.7% a year on average. The last full year, FY26, came in at ₹904 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹941 Cr.

FY26 revenue was ₹904 Cr, +18.9% on the year before.

Recent pace: the last four quarters grew +18.4% on average, against 12.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +18.4%, against +19.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +3.1%, against +6.6% a year (rolling over).

Windlas Biotech Ltd's operating margin was 11.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between 7.0% and 15.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.9 percentage points on the year while gross margin changed +0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 152% of Windlas Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹105 Cr of operating cash against ₹66.0 Cr of profit. After ₹76.0 Cr of spending on assets, ₹29.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 152% of profit came in as cash: the cash cycle got 94 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 3.1× depreciation over three years. The next section checks what that spending is building.

Windlas Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −24 days in FY26, down from 70 days in FY21. It spent ₹221 Cr on assets over the last 3 years. Customers take 92 days to pay, and stock sits for 40 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹904 Cr, each day of that cycle ties up about ₹2.5 Cr, so roughly −₹59.0 Cr is tied up in the business at any time.

FY26: customers took 92 days to pay and stock sat for 40 days, about 1.3 months of sales sitting as stock, for a full cycle of −24 days, shorter than FY21's 70.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 40 days. Customers pay about 92 days after that. Suppliers are paid at 156 days. Together that makes the −24-day cycle.

Spending on assets: ₹221 Cr over the last 3 years, against ₹72.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹60.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Windlas Biotech Ltd's P/E is 27.1×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 24.8×, over 5.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹31.68.

Why the multiple is where it is: over the past year earnings per share moved +8.8% while the price moved +0.4%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved +23.0% a year; about +25.6% a year came from earnings growth and about −2.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Windlas Biotech Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 16.8%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Windlas Biotech Ltd earned a ROCE of 16% in FY26. That is up from a low of 10% in FY17. Its return on capital used (ROIC) is 4.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.3% net margin and 1.00× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 7.3% net margin × 1.00× asset turnover × 1.56× leverage (assets divided by equity) ≈ 11.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 16.9% − 12.0% = +4.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

Windlas Biotech Ltd has total debt of ₹35.0 Cr against shareholder equity of ₹581 Cr as of Jun 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.06 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions cut their stake in Windlas Biotech Ltd by 3.0 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 7.2% of the company. Promoters moved +0.8 points over the same period, to 63.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: −3.0 points over 8 quarters, to 7.2%; Promoters: +0.8 points over 8 quarters, to 63.3%; Foreign institutions: +0.5 points over 8 quarters, to 2.1%.

Why the owners changed: domestic institutions drove it (−3.0 points), with the other side taken by promoters (+0.8 points). They reduced their stake.

For Windlas Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

47.6 out of 100, rank 14 of 24 in Pharma - API & CRAMS, with 81% of the evidence available.

Windlas Biotech Ltd scores 47.6 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 14. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 14.5 + 13.6 + 9.1 + 10.4 = 47.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Windlas Biotech ranks 14 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 47.6 out of 100.